person
as of 2026-07-01Clinical Development Lead
at a glance
Roles: Study Director
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Neurocrine Biosciences
Roles
Study Director
Trial investigator
no
Trials led
11
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818Phase 3Recruiting
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
NCT05545111Phase 2Completed
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098Phase 3Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
NCT05182476Phase 2Terminated
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
NCT07288333Phase 2Recruiting
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034Phase 3Recruiting
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
NCT05859698Phase 4Completed
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
NCT05654870Phase 3Terminated
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111Phase 4Recruiting
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157Phase 3Completed
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874Phase 3Recruiting
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
trial